WeVote
Log In

Bill

Bill

HB 3785

Relating to labeling requirements for compounded drug products.

89th Legislature (2025) Introduced by Barbara Gervin-Hawkins

Texas bill requiring specific labeling on compounded medications to enhance patient safety; failed committee consideration after substitute proposal.

Failed to receive affirmative vote in comm.
#health--general(i0385) #medicine&prescriptiondrugs(s7338) #occupationalregulation--healthoccupations(i0540) #packaging&labelingrequirements(s0339) #pharmacies&pharmacists(s1192) #pharmacy #texasstateboardof(v0022)
0
WeVote Research Nonpartisan
Bill Summary · HB 3785

Legislative bill overview

HB 3785 would establish labeling requirements for compounded drug products in Texas, likely mandating specific information be displayed on pharmaceutical compounds prepared by pharmacists. The bill was considered in committee but failed to advance after a committee substitute was proposed.

Why is this important

Compounded medications are custom-made drugs prepared by pharmacists for individual patients, often when commercially available options are unavailable or unsuitable. Clear labeling standards could improve patient safety by ensuring proper dosing and usage information, but they must balance regulatory burden against pharmacy operations and costs.

Potential points of contention

  • Pharmacy compliance costs: Compounding pharmacies may argue that detailed labeling requirements increase operational expenses, particularly for small independent pharmacies
  • Scope of required information: Disagreement likely exists over what specific details must appear (active ingredients, compounding date, stability information, warnings) versus what constitutes over-regulation
  • Federal vs. state authority: Questions may arise about whether state labeling mandates conflict with or duplicate FDA oversight of pharmaceutical compounds

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.